Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
| Status: | Archived |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2010 |
| End Date: | January 2011 |
Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA
High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the
bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry)
is a HIV medication that works by blocking the entry of HIV in cells including
monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the
addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high
levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of
infected monocyte/macrophages and to decrease in brain inflammation as studied by magnetic
resonance spectroscopy (MRS, a form of MRI study).
We found this trial at
1
site
Click here to add this to my saved trials
